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Clinical trials and research projects depend on valid and reliable outcome measures.1 
Here, there are several important questions, such as: is the measure validated for 
use in an MS population? Does the measure reflect the function that we are 
interested in? Is it reliable over time and between different raters? Moreover, 
researchers are increasingly interested in so-called “clinically meaningful” 
improvement on these measures, reflective of the (perceived) day-to-day functioning 
of patients. In other words, we are in great need for solid, robust and clinically 
meaningful measures in order to ‘tell the tale’ in clinical and therapeutic practice. 
While a (justified) critical attitude exists when it comes to novel measures 
materializing in the field of MS, we are relatively comfortable using measurements 
that have been around for a longer time.  However, the question is whether these 
measures are accepted in the field simply because they have stood the test of time or 
because they have outstanding psychometric properties and are the best within their 
category?  
This question formed the incentive for the MS Outcome Assessment Consortium 
(MSOAC)1-4 to write four in-depth reviews on some of the most commonly and widely 
used outcome measures in MS research:  the Symbol Digit Modalities Test (SDMT) 
for measuring information processing speed,2  the 9-hole peg test (9-HPT) for 
measuring manual dexterity performance,3 the Timed-25-Foot Walk (T25FW) as a 
metric of ambulation,4 and the Sloan low-contrast letter acuity (LCLA) test for 
measuring visual performance.5  
The overall aim of MSOAC is to adopt a clinical outcome assessment tool for clinical 
trials to better capture MS-related disability. The four companion papers in the 
current issue of Multiple Sclerosis Journal consistently and comprehensively describe 
the psychometric characteristics of the different outcome measures, their clinical 
relevance and they touch upon clinically meaningful change.  
A great advantage of the outcome measures discussed, is that they are fast, 
inexpensive, and relatively easy to administer. From that point of view, they are ideal 
candidates for use in clinical and scientific settings. The SDMT, which is already 
incorporated in several internationally renowned cognitive test batteries6-8, has an 
excellent ability to differentiate patients from healthy participants, a high test-retest 
reliability and sensitivity to detect changes over time using alternating but equivalent 
versions of the test. A score of 3 to 4 points difference on the SDMT can predict 
employment versus unemployment status, which can certainly count as a clinically 
meaningful change. 
The 9-HPT is currently regarded as the gold standard for manual dexterity in patients 
with MS due to its outstanding psychometric properties and serves as a reference 
point for other upper limb outcome measures. With caution, a 20% decrease in 9-
HPT score is associated with clinically meaningful worsening, but this should be 
further explored in future studies. The latter holds true for the T25FW test, as well: 
20% change in test score is associated with a significant worsening on self-reported 
physical health. An important note is that the T25FW is especially reliable and valid in 
a subset of MS patients (EDSS <6.5).  
Practical constraints such as fading of letters, backlighting, learning effects and the 
inability to recognize letters, make the LCLA is more difficult to work with. 
Nevertheless, LCLA is better at differentiating patients from healthy participants than 
high-contrast visual acuity tests and once the circumstances are ideal, the LCLA has 
a high reliability and validity. A seven point difference on the LCLA was suggested to 
be clinically meaningful by the MSOAC team.  
From the current MSOAC work by Benedict, Motl, Feys, Balcer and colleagues, it 
becomes clear that all four outcome measures (SDMT, 9-HPT, T25FW, LCLA) show 
firm reliability and validity for patients with MS. An encouraging outcome. Yet, it does 
not necessarily mean that ‘the measure can tell the tale’. As the authors mention, it is 
important to realize that one single measure of a specific function might not always 
be sufficient to explain every aspect of this particular function. For example, the 
T25FW test is described as ‘the best characterized objective measure of walking 
disability’, however it has a ceiling effect for patients with an EDSS of >6.5 and says 
something about speed of walking but not per se about the quality of gait.9 This 
means that there will always be a need for additional outcome measures testing 
related aspects of the same construct with at least similar psychometric properties, in 
order to give the best reflection of the patient’s functioning.    
We are able to tell the ‘statistical tale’. But there is more to pursue: in this day and 
age, where personalized medicine and patient-tailored care are central concepts, we 
need to identify changes on these outcome measures that have a clinical impact on 
our patients’ lives (e.g. what does a significant two-point improvement on the SDMT 
mean on a day-to-day basis?) For all four studied outcome measures, the first steps 
towards defining clinically meaningful change have been taken. These steps need to 
be validated and discussed by experts in the field, but the foundations have been laid 
to enable the measures tell a broader tale.    
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